Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: LGND stock price vs BMRN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMRN's multiple
Needs BMRN P/E.
Implied fair value · at LGND's multiple
Needs LGND P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: LGND FY 2025 (ended Dec 31, 2025) · BMRN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
LIGAND PHARMACEUTICALS INCORPORATED · implied price per share
Bear
$101.45
Base
$119.35
Bull
$137.25
BIOMARIN PHARMACEUTICAL INC · implied price per share
Bear
$25.74
Base
$30.28
Bull
$34.82
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.25x
0.06x
Net debt / EBITDA
Leverage against operating earnings
-2.31x
-3.03x
Cash and equivalents
Liquid reserves on the balance sheet
$733.52M
$2.11B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Royalty Pharma plc
LGND vs RPRX
Sarepta Therapeutics, Inc.
LGND vs SRPT
INCYTE CORP
LGND vs INCY
EXELIXIS, INC.
LGND vs EXEL
VERTEX PHARMACEUTICALS INC / MA
LGND vs VRTX
ALNYLAM PHARMACEUTICALS, INC.
LGND vs ALNY
REGENXBIO Inc.
LGND vs RGNX
IONIS PHARMACEUTICALS INC
LGND vs IONS
PTC THERAPEUTICS, INC.
LGND vs PTCT
$252.03M
$347.22M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe LGND can sustain its 60.4% revenue growth while preserving its 97.6% gross margin and 46.4% net margin, then holding or selectively buying on pullbacks can be justified; otherwise, the current price looks stretched because it already exceeds the P/E-implied value by 25.7% and sits above the DCF range.
LGND’s current price of $254.57 is 25.7% above the P/E-implied value of $189.14, indicating a valuation premium on this framework. That premium is partly justified by LGND’s much higher revenue growth and superior margin profile versus BMRN, but the stock is also above BMRN-implied range and the DCF range.
Supporting Metrics
